Trade Regeneron Pharmaceuticals, Inc. - REGN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 1.66 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Regeneron Pharmaceuticals Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 806.03 |
Open* | 808.95 |
1-Year Change* | 9.93% |
Day's Range* | 808.95 - 828.04 |
52 wk Range | 668.00-853.97 |
Average Volume (10 days) | 553.82K |
Average Volume (3 months) | 9.29M |
Market Cap | 87.03B |
P/E Ratio | 22.79 |
Shares Outstanding | 108.95M |
Revenue | 13.10B |
EPS | 35.05 |
Dividend (Yield %) | N/A |
Beta | 0.12 |
Next Earnings Date | Feb 1, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Nov 29, 2023 | 806.03 | 12.95 | 1.63% | 793.08 | 813.95 | 793.08 |
Nov 28, 2023 | 800.90 | 13.34 | 1.69% | 787.56 | 801.28 | 787.56 |
Nov 27, 2023 | 797.64 | -4.80 | -0.60% | 802.44 | 803.69 | 791.35 |
Nov 24, 2023 | 797.31 | 0.50 | 0.06% | 796.81 | 801.80 | 793.60 |
Nov 22, 2023 | 799.26 | 0.35 | 0.04% | 798.91 | 805.92 | 796.88 |
Nov 21, 2023 | 798.42 | -2.01 | -0.25% | 800.43 | 800.62 | 791.45 |
Nov 20, 2023 | 801.17 | 9.39 | 1.19% | 791.78 | 805.11 | 791.78 |
Nov 17, 2023 | 802.09 | 3.01 | 0.38% | 799.08 | 807.49 | 795.26 |
Nov 16, 2023 | 796.05 | -0.30 | -0.04% | 796.35 | 800.65 | 784.95 |
Nov 15, 2023 | 791.89 | 1.89 | 0.24% | 790.00 | 798.14 | 784.95 |
Nov 14, 2023 | 793.25 | -7.87 | -0.98% | 801.12 | 805.12 | 791.27 |
Nov 13, 2023 | 796.25 | 7.27 | 0.92% | 788.98 | 801.90 | 784.14 |
Nov 10, 2023 | 798.29 | -4.91 | -0.61% | 803.20 | 804.40 | 783.44 |
Nov 9, 2023 | 800.21 | -14.80 | -1.82% | 815.01 | 815.01 | 794.26 |
Nov 8, 2023 | 821.64 | -2.58 | -0.31% | 824.22 | 829.65 | 811.79 |
Nov 7, 2023 | 830.58 | -1.42 | -0.17% | 832.00 | 832.60 | 821.67 |
Nov 6, 2023 | 832.25 | 21.11 | 2.60% | 811.14 | 839.90 | 811.14 |
Nov 3, 2023 | 816.27 | -16.89 | -2.03% | 833.16 | 833.85 | 809.44 |
Nov 2, 2023 | 816.26 | 27.65 | 3.51% | 788.61 | 830.18 | 780.77 |
Nov 1, 2023 | 790.13 | 11.66 | 1.50% | 778.47 | 793.09 | 773.88 |
Regeneron Pharmaceuticals, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, February 1, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 Regeneron Pharmaceuticals Inc Earnings Release Q4 2023 Regeneron Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 12172.9 | 16071.7 | 8497.1 | 7863.4 | 6710.8 |
Revenue | 12172.9 | 16071.7 | 8497.1 | 7863.4 | 6710.8 |
Cost of Revenue, Total | 1560.4 | 2437.5 | 1119.9 | 782.2 | 434.1 |
Gross Profit | 10612.5 | 13634.2 | 7377.2 | 7081.2 | 6276.7 |
Total Operating Expense | 7434 | 7124.9 | 4920.5 | 5653.6 | 4176.4 |
Selling/General/Admin. Expenses, Total | 2115.9 | 1824.9 | 1346 | 1834.8 | 1556.2 |
Research & Development | 3592.5 | 2908.1 | 2735 | 3036.6 | 2186.1 |
Operating Income | 4738.9 | 8946.8 | 3576.6 | 2209.8 | 2534.4 |
Interest Income (Expense), Net Non-Operating | -19.6 | 328.8 | 139.1 | 88.1 | 13.7 |
Other, Net | 139.5 | 50.2 | 94.7 | 131.2 | 5.4 |
Net Income Before Taxes | 4858.8 | 9325.8 | 3810.4 | 2429.1 | 2553.5 |
Net Income After Taxes | 4338.4 | 8075.3 | 3513.2 | 2115.8 | 2376.4 |
Net Income Before Extra. Items | 4338.4 | 8075.3 | 3513.2 | 2115.8 | 2376.4 |
Net Income | 4338.4 | 8075.3 | 3513.2 | 2115.8 | 2444.4 |
Income Available to Common Excl. Extra. Items | 4338.4 | 8075.3 | 3513.2 | 2115.8 | 2376.4 |
Income Available to Common Incl. Extra. Items | 4338.4 | 8075.3 | 3513.2 | 2115.8 | 2444.4 |
Dilution Adjustment | |||||
Diluted Net Income | 4338.4 | 8075.3 | 3513.2 | 2115.8 | 2444.4 |
Diluted Weighted Average Shares | 113.5 | 112.2 | 115.1 | 114.6 | 114.8 |
Diluted EPS Excluding Extraordinary Items | 38.2238 | 71.9724 | 30.523 | 18.4625 | 20.7003 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | 40.4714 | 71.9724 | 30.523 | 18.4625 | 20.7003 |
Total Extraordinary Items | 68 | ||||
Other Operating Expenses, Total | -89.9 | -45.6 | -280.4 | ||
Unusual Expense (Income) | 255.1 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 3158.1 | 3162.1 | 3414.4 | 2936.2 | 2857.2 |
Revenue | 3158.1 | 3162.1 | 3414.4 | 2936.2 | 2857.2 |
Cost of Revenue, Total | 404.9 | 457.5 | 540.6 | 317.8 | 297.1 |
Gross Profit | 2753.2 | 2704.6 | 2873.8 | 2618.4 | 2560.1 |
Total Operating Expense | 2141.6 | 2215.4 | 2267.6 | 1712.5 | 1747.3 |
Selling/General/Admin. Expenses, Total | 652 | 601.1 | 660.5 | 529.1 | 476.3 |
Research & Development | 1085.3 | 1101.2 | 1043.1 | 911.3 | 794.3 |
Other Operating Expenses, Total | -0.6 | -0.5 | -6.6 | -45.7 | -17.4 |
Operating Income | 1016.5 | 946.7 | 1146.8 | 1223.7 | 1109.9 |
Interest Income (Expense), Net Non-Operating | 68.5 | -87.5 | 143 | 239 | -176.8 |
Other, Net | -2.1 | -1.2 | 34.9 | 47.1 | 30.1 |
Net Income Before Taxes | 1082.9 | 858 | 1324.7 | 1509.8 | 963.2 |
Net Income After Taxes | 968.4 | 817.8 | 1197.1 | 1315.7 | 852.1 |
Net Income Before Extra. Items | 968.4 | 817.8 | 1197.1 | 1315.7 | 852.1 |
Net Income | 968.4 | 817.8 | 1197.1 | 1315.7 | 852.1 |
Income Available to Common Excl. Extra. Items | 968.4 | 817.8 | 1197.1 | 1315.7 | 852.1 |
Income Available to Common Incl. Extra. Items | 968.4 | 817.8 | 1197.1 | 1315.7 | 852.1 |
Diluted Net Income | 968.4 | 817.8 | 1197.1 | 1315.7 | 852.1 |
Diluted Weighted Average Shares | 113.9 | 114 | 114.1 | 112.8 | 114 |
Diluted EPS Excluding Extraordinary Items | 8.50219 | 7.17368 | 10.4917 | 11.664 | 7.47456 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 8.50219 | 7.66579 | 10.7546 | 11.664 | 9.20263 |
Unusual Expense (Income) | 0 | 56.1 | 30 | 0 | 197 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 15884.1 | 14014.9 | 9779.1 | 7689.1 | 6447.6 |
Cash and Short Term Investments | 7742.3 | 5694.7 | 3587 | 3214.3 | 2809.9 |
Cash & Equivalents | 3105.9 | 2885.6 | 2193.7 | 1617.8 | 1467.7 |
Short Term Investments | 4636.4 | 2809.1 | 1393.3 | 1596.5 | 1342.2 |
Total Receivables, Net | 5328.7 | 6036.5 | 4114.7 | 2672.2 | 2243.2 |
Accounts Receivable - Trade, Net | 5328.7 | 6036.5 | 4114.7 | 2672.2 | 2243.2 |
Total Inventory | 2401.9 | 1951.3 | 1916.6 | 1415.5 | 1151.2 |
Prepaid Expenses | 411.2 | 332.4 | 160.8 | 387.1 | 243.3 |
Other Current Assets, Total | |||||
Total Assets | 29214.5 | 25434.8 | 17163.3 | 14805.2 | 11734.5 |
Property/Plant/Equipment, Total - Net | 3763 | 3482.2 | 3221.6 | 2890.4 | 2575.8 |
Property/Plant/Equipment, Total - Gross | 5432.2 | 4880.3 | 4352.7 | 3812.8 | 3304.5 |
Accumulated Depreciation, Total | -1669.2 | -1398.1 | -1131.1 | -922.4 | -728.7 |
Long Term Investments | 6640.1 | 6878 | 3194.8 | 3312.4 | 1800.5 |
Other Long Term Assets, Total | 2011.8 | 1059.7 | 967.8 | 913.3 | 910.6 |
Total Current Liabilities | 3141.3 | 3932.5 | 2697.4 | 2096.6 | 1442.8 |
Accounts Payable | 589.2 | 564 | 475.5 | 418.1 | 218.2 |
Accrued Expenses | 2073.9 | 1880.5 | 1502.3 | 1037.4 | 751.3 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 719.7 | |||
Other Current Liabilities, Total | 478.2 | 768.3 | 719.6 | 641.1 | 473.3 |
Total Liabilities | 6550.5 | 6666 | 6138 | 3715.5 | 2977.2 |
Total Long Term Debt | 2701.4 | 1980 | 2695.7 | 713.9 | 708.5 |
Capital Lease Obligations | 720 | 0 | 717.2 | 713.9 | 708.5 |
Other Liabilities, Total | 707.8 | 753.5 | 744.9 | 905 | 825.9 |
Total Equity | 22664 | 18768.8 | 11025.3 | 11089.7 | 8757.3 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Additional Paid-In Capital | 9949.3 | 8087.5 | 6716.2 | 4428.6 | 3911.6 |
Retained Earnings (Accumulated Deficit) | 23306.7 | 18968.3 | 10893 | 7379.8 | 5254.3 |
Treasury Stock - Common | -10353.3 | -8260.9 | -6613.3 | -739.9 | -396.4 |
Other Equity, Total | -238.8 | -26.2 | 29.3 | 21.1 | -12.3 |
Total Liabilities & Shareholders’ Equity | 29214.5 | 25434.8 | 17163.3 | 14805.2 | 11734.5 |
Total Common Shares Outstanding | 109.6 | 108.675 | 106.951 | 110.277 | 109.006 |
Long Term Debt | 1981.4 | 1980 | 1978.5 | ||
Intangibles, Net | 915.5 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 18634.8 | 16923 | 16909.2 | 15884.1 | 15428.6 |
Cash and Short Term Investments | 9913.6 | 8927.7 | 8959.7 | 7742.3 | 7021.7 |
Cash & Equivalents | 2152.3 | 1937.2 | 3916.3 | 3105.9 | 3491.3 |
Short Term Investments | 7761.3 | 6990.5 | 5043.4 | 4636.4 | 3530.4 |
Total Receivables, Net | 5584.5 | 5121.3 | 5118.6 | 5328.7 | 5548.3 |
Accounts Receivable - Trade, Net | 5584.5 | 5121.3 | 5118.6 | 5328.7 | 5548.3 |
Total Inventory | 2562 | 2507.7 | 2424.7 | 2401.9 | 2412.2 |
Prepaid Expenses | 574.7 | 360.8 | 406.2 | 411.2 | 446.4 |
Other Current Assets, Total | 5.5 | ||||
Total Assets | 32163.3 | 30657.5 | 30059.9 | 29214.5 | 27677.8 |
Property/Plant/Equipment, Total - Net | 4006.1 | 3922.6 | 3880.9 | 3763 | 3704.2 |
Long Term Investments | 5839.3 | 6405.5 | 6114.9 | 6640.1 | 6016.9 |
Other Long Term Assets, Total | 2665.9 | 2453.4 | 2226.2 | 2011.8 | 1724 |
Total Current Liabilities | 3598.6 | 3104.4 | 3100.1 | 3141.3 | 2879.2 |
Accounts Payable | 536.6 | 547.3 | 599.5 | 589.2 | 535.6 |
Accrued Expenses | 2644.7 | 2176 | 2074.3 | 2074.2 | 1796.4 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0 | |||
Other Current Liabilities, Total | 417.3 | 381.1 | 426.3 | 477.9 | 547.2 |
Total Liabilities | 7258.9 | 6639.6 | 6564.7 | 6550.5 | 6239 |
Total Long Term Debt | 2702.6 | 2702.2 | 2701.8 | 2701.4 | 2701.1 |
Long Term Debt | 1982.6 | 1982.2 | 1981.8 | 1981.4 | 1981.1 |
Capital Lease Obligations | 720 | 720 | 720 | 720 | 720 |
Other Liabilities, Total | 957.7 | 833 | 762.8 | 707.8 | 658.7 |
Total Equity | 24904.4 | 24017.9 | 23495.2 | 22664 | 21438.8 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.1018 | 0.1018 | 0.1018 | 0.1 | 0.1 |
Additional Paid-In Capital | 11251.5 | 10888.5 | 10597.7 | 9949.3 | 9518.2 |
Retained Earnings (Accumulated Deficit) | 26100.7 | 25092.9 | 24124.5 | 23306.7 | 22109.6 |
Treasury Stock - Common | -12271.1 | -11765.9 | -11045.5 | -10353.3 | -9914 |
Other Equity, Total | -176.802 | -197.702 | -181.602 | -238.8 | -275.1 |
Total Liabilities & Shareholders’ Equity | 32163.3 | 30657.5 | 30059.9 | 29214.5 | 27677.8 |
Total Common Shares Outstanding | 108.8 | 108.9 | 109.7 | 109.6 | 108.8 |
Intangibles, Net | 1017.2 | 953 | 928.7 | 915.5 | 804.1 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 4338.4 | 8075.3 | 3513.2 | 2115.8 | 2444.4 |
Cash From Operating Activities | 5014.9 | 7081.3 | 2618.1 | 2430 | 2195.1 |
Cash From Operating Activities | 341.4 | 286.2 | 235.9 | 210.3 | 148.2 |
Deferred Taxes | -746.4 | -147.1 | 75.6 | -130.6 | -140 |
Non-Cash Items | 1324.8 | 783.4 | 297 | 435 | 439.5 |
Cash Taxes Paid | 1502.4 | 1218.4 | 188.1 | 342.3 | 205.6 |
Cash Interest Paid | 53.7 | 55.8 | 23.2 | 25 | 22.3 |
Changes in Working Capital | -243.3 | -1916.5 | -1503.6 | -200.5 | -697 |
Cash From Investing Activities | -3784.6 | -5384.7 | -70.6 | -2027.8 | -1463 |
Capital Expenditures | -1616.9 | -551.9 | -614.6 | -429.6 | -383.1 |
Other Investing Cash Flow Items, Total | -2167.7 | -4832.8 | 544 | -1598.2 | -1079.9 |
Cash From Financing Activities | -1009 | -1005.8 | -1970.5 | -252.1 | -77.1 |
Financing Cash Flow Items | -445.7 | -1032.7 | -680.8 | -188 | -187.2 |
Issuance (Retirement) of Stock, Net | -563.3 | 26.9 | -3271.6 | -64.1 | 110.1 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 1981.9 | 0 | |
Net Change in Cash | 221.3 | 690.8 | 577 | 150.1 | 655 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 817.8 | 4338.4 | 3141.3 | 1825.6 | 973.5 |
Cash From Operating Activities | 1367.6 | 5014.9 | 3295 | 2666.1 | 2101.7 |
Cash From Operating Activities | 99.5 | 341.4 | 241.3 | 148.7 | 74.3 |
Deferred Taxes | -216.5 | -746.4 | -466.7 | -381 | -225 |
Non-Cash Items | 425.9 | 1324.8 | 1004.4 | 1030.9 | 455.7 |
Changes in Working Capital | 240.9 | -243.3 | -625.3 | 41.9 | 823.2 |
Cash From Investing Activities | -235.7 | -3784.6 | -1926.9 | -2119.2 | -1705.3 |
Capital Expenditures | -279.1 | -1616.9 | -1364.7 | -295.4 | -141.8 |
Other Investing Cash Flow Items, Total | 43.4 | -2167.7 | -562.2 | -1823.8 | -1563.5 |
Cash From Financing Activities | -322.5 | -1009 | -761.4 | -36.4 | 64.7 |
Financing Cash Flow Items | -97 | -445.7 | -256.6 | -147.7 | -98.8 |
Issuance (Retirement) of Stock, Net | -225.5 | -563.3 | -504.8 | 111.3 | 163.5 |
Net Change in Cash | 809.4 | 221.3 | 606.7 | 510.5 | 461.1 |
Issuance (Retirement) of Debt, Net | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Fidelity Management & Research Company LLC | Investment Advisor | 8.355 | 8918189 | -212604 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.2533 | 8809572 | 8422 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.6404 | 6020629 | -41844 | 2023-06-30 | LOW |
Capital World Investors | Investment Advisor | 5.1999 | 5550382 | -280204 | 2023-06-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 4.727 | 5045619 | 136204 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.6757 | 4990870 | 97254 | 2023-06-30 | LOW |
Capital International Investors | Investment Advisor | 2.7699 | 2956615 | 803143 | 2023-06-30 | LOW |
Dodge & Cox | Investment Advisor/Hedge Fund | 2.2432 | 2394355 | 9654 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.1371 | 2281129 | 63136 | 2023-06-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 1.9735 | 2106541 | 74167 | 2023-06-30 | LOW |
Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.7036 | 1818471 | -10055 | 2023-09-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 1.5635 | 1668932 | -98987 | 2023-06-30 | LOW |
Loomis, Sayles & Company, L.P. | Investment Advisor/Hedge Fund | 1.1968 | 1277484 | -34923 | 2023-06-30 | LOW |
Yancopoulos (George D) | Individual Investor | 1.1452 | 1222370 | -16824 | 2023-04-11 | |
Putnam Investment Management, L.L.C. | Investment Advisor/Hedge Fund | 1.0955 | 1169321 | 4004 | 2023-06-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.9054 | 966467 | 84157 | 2022-12-31 | LOW |
American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 0.8307 | 886668 | -75042 | 2023-06-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7936 | 847129 | -1998 | 2023-06-30 | LOW |
BlackRock Asset Management Ireland Limited | Investment Advisor | 0.7587 | 809811 | -9968 | 2023-06-30 | LOW |
Neuberger Berman, LLC | Investment Advisor/Hedge Fund | 0.6639 | 708663 | 19784 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Regeneron Company profile
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.Industry: | Bio Therapeutic Drugs |
777 Old Saw Mill River Road
TARRYTOWN
NEW YORK 10591
US
Income Statement
- Annual
- Quarterly
News

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com